Highest-materiality recent filing
Company may issue and sell up to $20M of common stock through ATM program with A.G.P./Alliance Global Partners.
Credit agreement amended with Callodine Commercial Finance on Nov 5, 2025.
DarioHealth launches strategic review, raises $17.5M via private placement
Board formed Special Committee, engaged Perella Weinberg as advisor to explore sale, merger, or standalone.
DarioHealth accelerates mandatory conversion of Series C & D preferred stock into common stock
Effective Sept 18, 2025: all outstanding Series C, C-2, D, D-1, D-2, D-3 preferred convert to common stock or pre-funded warrants at holder's election.
DarioHealth regains Nasdaq minimum bid price compliance; deficiency closed
Received Nasdaq notice on Sep 12, 2025 confirming compliance with Rule 5550(a)(2).
DarioHealth enters $32.5M credit agreement with Callodine; warrants issued
Borrowed $32.5M at closing; may draw up to $17.5M more subject to revenue thresholds and lender discretion.
DarioHealth CFO Zvi Ben-David resigns; Chen Franco-Yehuda appointed CFO effective May 15, 2025
Zvi Ben-David resigns as CFO, Treasurer, Secretary effective May 15, 2025; departure for personal reasons, not due to any disagreement.
DarioHealth receives Nasdaq extension to Sept 15, 2025 to regain $1 bid price
Staff granted additional 180 days until September 15, 2025 to meet Minimum Bid Price Requirement.
DarioHealth closes $25.6M private placement; targets cash flow positive by end of 2025
Raised $25.6M via convertible preferred stock at conversion prices of $0.73 and $0.83; majority from existing shareholders.
DarioHealth Raises ~$6.8M via Series D Convertible Preferred Private Placement
Sold 4,974 shares of Series D-2 and 1,850 shares of Series D-3 preferred at $1,000 each for ~$6.8M gross.
DarioHealth raises ~$18.8M via preferred stock; amends Avenue loan to extend maturity
Closed private placement of 7,055 Series D and 11,750 Series D-1 preferred shares at $1,000 each, raising $18.8M.
DarioHealth receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notice on Sept 16, 2024: closing bid price below $1.00 for 30 consecutive business days.
DarioHealth appoints Steven Nelson as CCO; President Richard Anderson departs
Steven Nelson, formerly CEO of Contigo Health (Premier Inc.), named Chief Commercial Officer effective June 5, 2024.
On April 18, 2025, the Board of Directors of the Company appointed Chen Franco-Yehuda, age 41, to serve as the Company’s Chief Financial Officer, Treasurer and Secretary, effective as of May 15, 2025.
On April 18, 2025, Mr. Zvi Ben-David resigned as Chief Financial Officer, Treasurer and Secretary of DarioHealth Corp. (the “Company”), effective as of May 15, 2025.
On February 25, 2025, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, appointed Lawrence Leisure as a member of the Board, effective immediately.
On February 24, 2025, Jon Kaplan voluntarily resigned from his position as a member of the Board.
the Company and Richard Anderson, the Company’s President, mutually agreed for Mr. Anderson to cease serving in his role as President of the Company.
appointed Steven Nelson, age 51, to serve as its Chief Commercial Officer.
Max materiality 0.80 · Median 0.50 · Most common event other_material